Drugs / ocaratuzumab
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01858181 | Jan → Dec 2015 | B-cell non-Hodgkin lymphoma | Mentrik Biotech, LLC | Unknown | No outcome recorded |
| Phase 1 | NCT00354926 | Jul 2006 → Jan 2009 | non-Hodgkin lymphoma | Applied Molecular Evolution | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ocaratuzumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01858181 ↗ |
| Known as | AME-133v | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00354926 ↗ |
| Known as | LY2469298 | “AME-133v (LY2469298)” NCT00354926 ↗ |
| Modality | Monoclonal antibody | “Ocaratuzumab is a third-generation, fully humanized IgG1 monoclonal antibody (mAb)” NCT01858181 ↗ |
| Route | Intravenous | “weekly intravenous infusions of AME-133v” NCT00354926 ↗ |
| Target | MS4A1 | “B-lymphocyte antigen CD20 binding agent” CHEMBL2109665 ↗ |